Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotechs Brace to Battle a Deadly GI Bacterium

This article was originally published in Start Up

Executive Summary

C. difficile is the number one cause of infectious diahrrea in the developed world. Long thought to be a nuisance, the infections are turning deadly, and a spate of outbreaks has occurred at hospitals in the US, Canada, and Europe. Biotechs are racing to develop new therapeutics to combat the killer bug.

You may also be interested in...



Optimer Looks To Partner C. Diff Candidate After Trial Success

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

Optimer Looks To Partner C. Diff Candidate After Trial Success

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

Optimer Rides High After OPT-80 C. Diff Trial Success

Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel